Ikaria Acquisition Diversifies And Strengthens Mallinckrodt’s Hospital Care Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
But, with its $2.3 billion purchase price, Mallinckrodt is betting it can withstand a patent challenge to INOmax, an inhaled nitric oxide drug/device combo product, from an industrial gas company.
You may also be interested in...
Terlivaz Approved By FDA As Mallinckrodt Seeks To Advance New Business Strategy
Terlivaz is the first product approved to improve kidney function in adults with hepatorenal syndrome (HRS). The approval is a milestone in a long regulatory road for the drug.
In Split, Ikaria Looks For Products, While New R&D Play Preps For IPO
In a partial buy-out by new private equity investor Madison Dearborn Partners, Ikaria is refocused on building out its critical care product portfolio, while a new R&D spin-out may take a route to the public markets. Existing investors have already done nicely through a series of dividends.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.